Satellite Symposia

Satellite Symposia are non-commercial, industry-supported scientific sessions created to complement the official program and to extend the educational experience of meeting attendees. Satellite Symposia may include one or a number of speakers and topics, and will contain objectivity in the presentation. Satellite Symposia are not part of the official asm2015 scientific sessions as planned by the General Meeting Program Committee.




Career Track Options in Germany – Steps Towards a Successful Scientific Career
Supported by Research in Germany
11:30 a.m. – 1:30 p.m.
Ernest N. Morial Convention Center
Meeting Room 239

Speakers by Topic:
Research and Career Opportunities in Microbiology in Germany
Antje Boetius, Member of the German Council for Science and Humanities, Max Planck Institute for Marine Microbiology and Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research

Funding Programs to Support Your Research Career
Anke Deggerich, Program Officer, German Research Foundation (DFG), Bonn

A Road to Scientific Independence
Kenneth M. Pfarr, Junior Group Leader, Institute for Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn

How to Write a Good Grant
Andreas Strecker, Program Officer, German Research Foundation (DFG), Bonn

Program Overview:
The workshop will be directed towards researchers in the early stages of their scientific careers and will provide an overview of research funding and career opportunities in Germany. Program officers from the head office of the German Research Foundation (DFG) will discuss funding programs offered by various funding organizations as well as the application and review procedures. Attendees of the workshop will learn about fellowships for postdoctoral researchers, programs to establish an independent research group and individual funding opportunities.

Furthermore, scientists working in Germany will share their personal experiences and discuss their scientific careers and grant writing processes. They will give an overview of the German research landscape, point out opportunities for collaboration and provide information on how to find the right lab for your research interests.
We will provide for networking opportunities following the presentations.
During this portion of the event young scientists will have the opportunity to make new contacts and discuss their individual career plans with experts in an informal setting.


Revolutions in the Clinical Microbiology Lab … The Art of Imaging
Supported by BD Diagnostics
6:30 p.m. – 7:30 p.m.
New Orleans Marriott
555 Canal Street
Meeting Room: Mardi Gras Ballroom, Salon D

Richard B. (Tom) Thomson, Jr., PhD, D(ABMM), FAAM
Medical Microbiologist, NorthShore University HealthSystem, The University of Chicago Pritzker School of Medicine

Antony Croxatto, PhD
University Hospital of Lausanne, Switzerland, Institute of Microbiology

Patrick Murray, PhD
WW Director Scientific Affairs, BD Diagnostics

Program Overview:
The BD supported Symposia will address advances in Clinical Microbiology Laboratory Automation focusing on experiences implementing solutions, laboratory change management and future enhancements. Advancements in digital microbiology will be presented with discussion around clinical applications today and in the future.



The Need for Real-Time Answers for MDRO Detection and Therapy Guidance
Supported by GeneWEAVE, Inc.
6:30 a.m. – 7:30 a.m.
JW Marriott New Orleans
614 Canal Street
Orleans/Rosalie/St. Claude

Lance Peterson MD, FASCP
Director, Microbiology and Infectious Disease Research, NorthShore University HealthSystem, Evanston, IL

Program Overview:
The goals for this workshop will be to:

    • Present an overview of MDROs
    • Review the outcomes of surveillance programs when diagnostic tests are utilized that provide results within the same-shift
    • Discuss the need for real-time susceptibility information to further support antibiotic stewardship programs and improve clinical outcomes.
    • Introduce a novel technology that will provide sample-in/susceptibility-out solutions for same-shift bacterial detection and susceptibility answers directly from samples.


New Phenotypic Susceptibility Technology: Impact on Clinical Microbiology and Antimicrobial Stewardship
Supported by Accelerate Diagnostics
6:30 p.m. – 8:30 p.m.
Le Méridien Hotel
333 Poydras St, New Orleans
Esplanade Ballroom

Session Moderator:
Karen Carroll, MD, Professor of Pathology and Medicine, The Johns Hopkins University School of Medicine

Speakers by Topic:
6.30 p.m. – 7.00 p.m.
Resistance Genotype vs. Susceptible Phenotype
Paul Schreckenberger, P.D, D(ABBM), F(AAM), Director, Clinical Microbiology Laboratory, Loyola University Medical Center

7.00 p.m. – 7.30 p.m.
Focus on New Technology: 5 Hour Phenotypic Susceptibilities Direct from Positive Blood Culture
Connie Price, MD, Chief, Division of Infectious Diseases, Denver Health Medical Center

7.30 p.m. – 8.00 p.m.
Antimicrobial Stewardship: Moving Beyond Rapid Identification to High Speed Susceptibility
James S. Lewis II, PharmD, FIDSA, ID Clinical Pharmacy Coordinator, Oregon Health and Science University

8.00 p.m. – 8.20 p.m.
Question & Answer Panel Discussion – Hosted by Moderator

Program Overview:
Providing phenotypic antimicrobial susceptibility results to clinicians is one of the most important activities performed in the clinical microbiology laboratory and has direct relevance to the care of patients with infection. Although there have been recent advances in genotypic identification of resistance mechanisms, clinicians still have to wait several days to obtain phenotypic susceptibility results. This program will review many of the scientific issues of genotypic and phenotypic diagnostic test and their potential impact on clinical management of patients with serious infections. Additionally, this program will introduce a sample-to-answer platform that provides 1 hour Identification and 5 hour MIC antimicrobial susceptibility results direct from samples such as positive blood cultures, respiratory specimens and skin and wound swabs. The program moderator will host a Q & A session and brief panel discussion.


Standing Up to Superbugs: Technologies to Improve Management of Multidrug-Resistant Organisms
Supported by OpGen Inc.
6:30 p.m. – 8:30 p.m.
Downtown Marriott at the Convention Center
859 Convention Center Boulevard
River Bend 2

Speakers by Topic:
Managing Patients at Risk for MDRO Colonization and Infection
Keith S. Kaye, MD, MPH, Professor of Medicine, Corporate Vice President of Quality and Patient Safety Corporate Medical Director, Infection Prevention, Epidemiology and Antimicrobial Stewardship, Detroit Medical Center and Wayne State University Health Center

The Benefits of Molecular Screening and Surveillance for MDROs
Lance R. Peterson, MD, Director of Microbiology and Infectious Diseases Research , Epidemiologist Departments of Pathology/Lab Medicine and Medicine, NorthShore University HealthSystem Clinical Professor University of         Chicago Pritzker School of Medicine

Real-Time Genome Sequencing of Multidrug-Resistant Bacteria Enables Cost-Effective High Resolution Detection and Refutation of Nosocomial Transmissions
Dag Harmsen, MD, Professor of Medical Microbiology, University of Münster, Germany

Advancing MDRO DNA Detection & Bioinformatics: Acuitas™ MDRO Tests and New Developments from OpGen
Terry Walker, PhD, Sr. Vice President, R&D, OpGen

Program Overview:
Multidrug-resistant Organisms (MDROs) continue to be one of our most serious health threats globally. In the US alone, the CDC reports that each year 2 million people are affected and 23,000 will die from these infections. Carbapenem-resistant Enterobacteriaceae (CRE) outbreaks in our health care systems are now reported more frequently, causing both patient treatment and infection control challenges. At our symposium, speakers will discuss the patients threatened most by MDROs and the infection control challenges, novel genomic sequencing approaches to improve our understanding of transmission events, and the benefits of OpGen’s current and future Acuitas MDRO Tests and bioinformatics solutions to combat and control MDROs.


Explore New Microbiology apps to accelerate and simplify your biological interpretation
Supported by Illumina, Inc.
6:30 p.m. – 8:30 p.m.
Bourbon Vieux
203 Bourbon Street

Raymond Tecotzky, Market Manager, Informatics Ecosystem

Program Overview:
Discover how easy it is to create and use Microbiology apps to streamline data analysis. Move through the sequencing workflow seamlessly — from sample preparation to biological interpretation of data. BaseSpace is Illumina’s genomics computing environment for next-generation sequencing (NGS) data analysis. This flexible solution is available in both cloud and onsite packages. Now sequencing labs can easily and securely analyze, archive, and share sequencing data, and informaticists can simplify and accelerate NGS data analysis with push-button tools.


Implementing T2Candida for high risk patients: the impact on hospital mortality, economics and resistance
Supported by T2 BioSystems
6:30 p.m. – 8:30 p.m.
Downtown Marriott at the Convention Center
859 Convention Center Boulevard
Blaine Kern Ballroom

Michael Pfaller, MD
Chief Medical Officer, T2 Biosystems
Professor Emeritus, University of Iowa College of Medicine and College of Public Health, Iowa City, IA

Kevin W. Garey, PharmD, MS
Professor and Chair, Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy

Angela M. Caliendo, MD, PhD
Professor and Executive Vice Chair, Department of Medicine, Alpert Medical School of Brown University

Pinar Bilir, BS, MS
Director, US HEOR and Real World Evidence Solutions, IMS Health, Danbury, CT

Luis Ostrosky-Zeichner, MD
Professor of Medicine and Epidemiology, Director, Laboratory of Mycology Research, Division of Infectious Diseases, University of Texas Medical School, Houston TX

Program Overview:
The U.S. Centers for Disease Control and Prevention, or the CDC, recently called antifungal resistance ‘‘one of our most serious health threats” in the United States. Join a panel of leading experts that will discuss how the application of the T2Candida Panel may deliver significant improvements in patient outcomes while reducing hospital costs, mortality and antifungal resistance. The discussion will include best practices in the management of patients at risk for Candida infections and the methods that can be deployed to decrease the growing threat of resistant pathogens.